You are here

NANOFIBER TECHNOLOGY IN SMALL-DIAMETER VASCULAR GRAFTS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL068334-01A1
Agency Tracking Number: HL068334
Amount: $100,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BIOMOD SURFACES 125 BRIDGE RD
SALISBURY, MA 01952
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DONALD DEMPSEY
 (978) 465-0967
 DDEM764124@AOL.COM
Business Contact
 DEMPSEY J
Phone: (978) 465-0967
Email: DDEM764124@AOL.COM
Research Institution
 BETH ISRAEL DECONESS
 
BETH ISRAEL DECONESS
BOSTON, MA 02115
United States

 Domestic Nonprofit Research Organization
Abstract

There is no small-diameter vascular prosthesis that is capable of emulating the biologic and physical properties of the normal arterial wall. The goal of this proposal is to develop a small-diameter prosthetic vascular graft using nanofiber technology. Our hypothesis is creating a nanofibrous vascular graft by electrospinning an ionic polyurethane will result in a graft that possesses properties similar to that of native artery. The potent anti-thrombin agent recombinant hirudin (rHir) will be covalently bound to functional groups within the polymer, resulting in an anti-thrombotic surface. The elastic properties of the ionic polymer will provide circumferential compliance, with longitudinal stretch and kink- resistance prevented by a thin braided Dacron mesh within the graft wall. The specific objectives are to: 1) optimize electrospinning methodology, 2) develop a Dacron inner-wall reinforcement, 3) electrospin PEU grafts containing reinforcement, 4) characterize physical and chemical properties, 5) covalently link rHir to PEU grafts, 6) characterize surface antithrombin properties, 7) evaluate blood interaction with grafts and 80 assess surface rHir stability under simulated arterial flow conditions. Phase II of this project will evaluate these PEU grafts in a canine carotid artery model. Development of a bioactive small-diameter vascular graft would have a significant impact on small vessel repair and replacement. PROPOSED COMMERCIAL APPLICATIONS: Development of a bioactive small-diameter vascular graft would have a significant impact on small vessel repair and replacement. These grafts could be utilized in peripheral bypass as well as for coronary artery bypass, which have some 500,000 grafts are implanted annually in the United States. For example, the potential annual market value for an "off-the-shelf" synthetic coronary artery bypass graft could exceed $1.5 billion.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government